Post Reply
81-100 of 166
Both Accrelist and Beverly are in the same asethetic business. One is mainly focusing in SG while the other in MY.
Any chances that both might merge and grow together as one?
Worth thinking?
Any chances that both might merge and grow together as one?
Worth thinking?
Accrelist: Expands Its Network Of Medical Aesthetic Clinics, Launches Its 7th Local Clinic At Raffles City Shopping Centre.
Original Post fromShareInvestor Express
$Accrelist Ltd(QZG.SI) Accrelist Ltd. continues to expand its local network of medical aesthetic clinics with the opening of its first city centre clinic at 252 North Bridge Road, #B2-06/07, Raffles City Shopping Centre. The Raffles City clinic is Accrelist Medical Aesthetics' premium flagship clinic. It further complements A.M Aesthetics' existing island wide network of clinics located in heartland areas following the opening of its Serangoon Central clinic in April 2021. The Raffles City clinic has ten treatment rooms, instead of the usual four treatment rooms, and has a display and demonstration counter featuring A.M Skincare products...
Other Aesthetic Company reporting profits. This company still raising money from people....
Corporate presentation
https://links.sgx.com/FileOpen/Beverly%20JCG%20Corporate%20Information%20%20AGM%20%20280621%20Final.ashx?App=Announcement& FileID=672725
Their focus appears to be plastic surgery in the healthcare sector as seen from response to SIAS
Response to SIAS
Can management provide shareholders with greater clarity on the envisaged contribution from each sub-segment (e.g. aesthetic services, dental services, health maintenance procedures) under the now expanded aesthetic medical and healthcare segment?
Company&rsquo s Response The FY2020 contribution of revenue from each sub-segment is as follows:
Sub-Segment FY2020 (%)
Cosmetic Surgery 61%
Aesthetics 25%
Wellness/Anti-Aging 5%
Dental 3% Others 6%
Total 100%
With the expansion of our aesthetic and dental business from FY2021 onwards, the Group expects the contribution of revenue from the Aesthetics and Dental sub-segments to increase going forward.
https://links.sgx.com/FileOpen/Beverly%20JCG%20Corporate%20Information%20%20AGM%20%20280621%20Final.ashx?App=Announcement& FileID=672725
Their focus appears to be plastic surgery in the healthcare sector as seen from response to SIAS
Response to SIAS
Can management provide shareholders with greater clarity on the envisaged contribution from each sub-segment (e.g. aesthetic services, dental services, health maintenance procedures) under the now expanded aesthetic medical and healthcare segment?
Company&rsquo s Response The FY2020 contribution of revenue from each sub-segment is as follows:
Sub-Segment FY2020 (%)
Cosmetic Surgery 61%
Aesthetics 25%
Wellness/Anti-Aging 5%
Dental 3% Others 6%
Total 100%
With the expansion of our aesthetic and dental business from FY2021 onwards, the Group expects the contribution of revenue from the Aesthetics and Dental sub-segments to increase going forward.
Auditor' s Responsibilities for the Audit of the Financial Statements
Our responsibility is to conduct an audit of the Group& rsquo s financial statements in accordance with Singapore Standards of Auditing and to issue an auditor' s report. However, because of the matters described in the Bases for Disclaimer of Opinion section of our report, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.
We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority (ACRA) Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code.
Report on Other Legal and Regulatory Requirements In our opinion, in view of the significance of the matters referred to in the Bases for Disclaimer of Opinion section of our report, we do not express an opinion on whether the accounting and other records required by the Act to be kept by the Company and by those subsidiary corporations incorporated in Singapore of which we are the auditors, have been properly kept in accordance with the provisions of the Act. The engagement director on the audit resulting in this independent auditor' s report is Meriana Ang Mei Ling.
Nexia TS Public Accounting Corporation Public Accountants and Chartered Accountants
The auditors of the Company, Messrs Nexia TS Public Accounting Corporation, have expressed their intention not to seek for re-appointment at this AGM. The Board of the Company shall be taking the necessary steps to replace the independent auditors of the Company, in consultation with the Audit Committee of the Company, with another firm of auditors. Shareholders& rsquo approval for the appointment of the incoming independent auditors of the Company will be sought at a forthcoming Extraordinary General Meeting (& ldquo EGM& rdquo ) of the Company, the details of which will be made known to shareholders in due course. Messrs Nexia TS Public Accounting Corporation shall stay on as the interim auditors of the Company until the appointment of the incoming independent auditors at the next EGM.
Our responsibility is to conduct an audit of the Group& rsquo s financial statements in accordance with Singapore Standards of Auditing and to issue an auditor' s report. However, because of the matters described in the Bases for Disclaimer of Opinion section of our report, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these financial statements.
We are independent of the Group in accordance with the Accounting and Corporate Regulatory Authority (ACRA) Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities (ACRA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code.
Report on Other Legal and Regulatory Requirements In our opinion, in view of the significance of the matters referred to in the Bases for Disclaimer of Opinion section of our report, we do not express an opinion on whether the accounting and other records required by the Act to be kept by the Company and by those subsidiary corporations incorporated in Singapore of which we are the auditors, have been properly kept in accordance with the provisions of the Act. The engagement director on the audit resulting in this independent auditor' s report is Meriana Ang Mei Ling.
Nexia TS Public Accounting Corporation Public Accountants and Chartered Accountants
The auditors of the Company, Messrs Nexia TS Public Accounting Corporation, have expressed their intention not to seek for re-appointment at this AGM. The Board of the Company shall be taking the necessary steps to replace the independent auditors of the Company, in consultation with the Audit Committee of the Company, with another firm of auditors. Shareholders& rsquo approval for the appointment of the incoming independent auditors of the Company will be sought at a forthcoming Extraordinary General Meeting (& ldquo EGM& rdquo ) of the Company, the details of which will be made known to shareholders in due course. Messrs Nexia TS Public Accounting Corporation shall stay on as the interim auditors of the Company until the appointment of the incoming independent auditors at the next EGM.
RESULTS OF THE RIGHTS CUM WARRANTS ISSUE
2.1 Level of Subscription
Further to the Previous Announcements, the Directors wish to announce that, based on
the total issued share capital of the Company comprising 15,814,936,164 Shares as at
the Record Date, 5,271,645,388 Rights Shares with 5,271,645,388 Warrants were
available for subscription under the Rights Cum Warrants Issue. As at the close of the
Rights Cum Warrants Issue on 25 May 2021, being the Closing Date, valid acceptances
and excess applications were received for a total of 2,112,779,425 Rights Shares with
Warrants, representing approximately 40.08% of the total number of 5,271,645,388 Rights
Shares with Warrants available under the Rights Cum Warrants Issue.
Good Luck!
SGX Monitoring this company very carefully.
Good , keep it up with the buying momentum. Cheers. Huat !!!
This share aka Albedo got BB inside ?...right share at 1 pip quite safe to buy...medical stock won't die one...
SmallSmall ( Date: 29-Apr-2021 15:39) Posted:
|
Lol..Suddenly so many micro penny stock to occupy top 10 volume.
This one ex -rights liao....1 for 3 @ $0.001 with 1 free warrant.
Seller $0.001
Seller $0.001
My take is just let the owners and stake holders take up their allocations and let them waste their money.
So many announcements... Pray that you can sell at 0.001 first.
Good luck with your rights subscription.
bishalnb ( Date: 06-May-2021 08:27) Posted:
|
so what now for Beverly
SmallSmall ( Date: 29-Apr-2021 15:39) Posted:
|
Ex Rights on 4 May 2021. 1 for 3 @ $0.002 with 1 free warrant
Plan. Buy cum @ $0.001 and sell ex at $0.001.
Then subscribe for rights @ $0.001 to get free warrant and sell mother @ $0.001.
Keep the free warrant. If can sell warrant @ $0.001, 100% return.
Of course provided can sell mother @ $0.001 haha
Plan. Buy cum @ $0.001 and sell ex at $0.001.
Then subscribe for rights @ $0.001 to get free warrant and sell mother @ $0.001.
Keep the free warrant. If can sell warrant @ $0.001, 100% return.
Of course provided can sell mother @ $0.001 haha
Kanna SGX Query and company' s replies seems weak.
This company really idiotic. Revenue and losses almost similar. Then I rather the company have no Revenue and then losses will be zero too...hahaha
Result coming out soon
If you board the treasureship at 0.1 cent, it has already move to 0.1/0.2 cent. It is a waiting game.
darkhorse88 ( Date: 24-Feb-2021 11:25) Posted:
|
Erm.... BB no ammo ah?
sklong138 ( Date: 15-Feb-2021 16:09) Posted:
|